Introduction
Triple-negative breast cancer (TNBC, ER-/PR-/HER2 normal) is characterized by aggressive disease progression with early dissemination to distant organs [1] [2] [3] . Gene expression profiling of breast cancer tumors identified at least five molecular subtypes of breast cancer; Luminal A and B, HER2+, basal-like, and claudin-low 4, 5 . Basal-like breast cancers are characterized as high grade, with low or no expression of ER and HER2, and generally high expression of HER1 and basal cytokeratins 5/6 or 14 6, 7 . While the TNBC and basal-like subtypes significantly coincide, discrepancies of 20-30% between the two subtypes have been reported 8, 9 .
Mass spectrometry-based proteomics holds great promise in biomarker and therapeutic target discovery, but there are significant inconsistencies between the number of reported cancer protein biomarkers and possible targets and rate at which FDA-approved protein biomarkers are credentialed 10, 11 . To date, no targeted therapies against TNBC have successfully transitioned to clinic use, although clinical trials with PI3K/AKT inhibitors 12, 13 , immune checkpoint inhibitors 14 , VEGF inhibitors [15] [16] [17] and PARP inhibitors [18] [19] [20] have shown promising results. Cytochrome P450 reductase (CYPOR, also referred to as POR, CPR, OR, NCPR, P450R) is an endoplasmatic reticulum-associated flavoprotein that functions as an essential stepwise, two-electron, donor in multiple oxygenase enzymes, particularly microsomal cytochrome P450 monooxygenases [21] [22] [23] . CYPOR contains one FAD-containing FNR-like (FAD) and one FMN-containing a flavodoxin-like (FMN) domain 21 . The functional microsomal cytochrome P450 complex is made up of one of fifty P450 monooxygenases and one unique CYPOR 21, 22 . CYPOR is involved in numerous other enzymes and biological pathways, chiefly steroid and drug metabolism 22, 24, 25 . Due to this functionality, many cancer studies involving CYPOR have focused on its role in reducing anticancer prodrugs, e.g. doxorubicin 26 , mitomycin C 27 and PR-104A 28 .
CYPOR was initially identified in a hypothesis-driven proteomic study of 44 primary TNBC tumors and 10 corresponding metastases 29 . In this study, we evaluated CYPOR expression in five cohorts of TNBC or basal-like breast cancer patients to evaluate whether it may serve as a prognostic biomarker for TNBC patients. These analyses demonstrated a clear correlation between high gene or protein CYPOR levels and shorter time to recurrence in TNBC and basal-like breast cancer patients. To the best of our knowledge, this correlation between CYPOR expression and disease outcome in TNBC patients has not previously been shown.
Materials and Methods

Patient tissue samples for mass spectrometric analysis
Our mass spectrometric analysis involved two formalin-fixed, paraffin-embedded (FFPE) TNBC patient tissue cohorts (cohort 1, n = 34 and cohort 2, n = 20, respectively) ( Fig 1) .
Inclusion criteria for cohort 1 were: TNBC status verified by immunohistochemistry (IHC), <70 years of age at time of diagnosis, 10 years follow-up post-diagnosis, tumor-negative lymph node status (N-) for the recurrence-free patient group and grade 2 or higher. Cohort 1 consisted of primary tumors of 34 TNBC patients diagnosed and treated at Odense University Hospital (OUH) between 1997 and 2006. Cohort 2 consisted of primary tumors and their corresponding distant metastatic lesions from 10 TNBC patients. Inclusion criteria for cohort 2 were: TNBC status verified by IHC for the primary and corresponding distant metastases, ≤50mm primary tumor size at diagnosis, axillary lymph node metastasis allowed, grade 2 or higher, and no distant metastatic lesions at time of primary tumor diagnosis. All primary tumors of cohort 2 were diagnosed and treated initially at OUH, while post-metastatic treatment was performed at various hospitals in Denmark.
Clinicopathological patient data including time to recurrence, age at diagnosis, lymph node status, tumor size at diagnosis, time to death and adjuvant chemotherapy treatment were obtained from the Danish Breast Cancer Group. Study approval was acquired from the Regional Scientific Ethical Committee of Southern Denmark (S-2008-0115).
Laser capture and protein extraction
The tissue processing and mass spectrometry analysis has been described in detail elsewhere 29 . Briefly, between 2 to 9 sections (7 μm), depending on cancer cell content, were cut from each FFPE breast cancer block on a microtome, mounted on 1.5 µm PEN membrane slides (Olympus, Ballerup, Denmark) and air dried. Slides were deparaffinized in xylene (3 x 5 min) followed by hydration in three alcohol gradients (100%, 96% and 70%) and H 2 O for 3, 2, 1 and 1 min, respectively. Sections were stained with Mayer's hematoxylin and Eosin for 15 and 5 seconds, respectively, rinsed with water, 96% ethanol and air-dried. Dissection was carried out on a Cell Cut Plus instrument (MMI AG, Glattbrugg, Switzerland). Areas of interest (cancer cells) for laser capture microdissection (LCM), based on morphology, were marked on a touchscreen using a 10x objective and dissected under optimized cutting conditions. Dissected tissue was collected on adhesive IsolationCaps (MMI AG, Glattbrugg, Switzerland). The minimum required sample was 5,000,000 μm 2 corresponding to 5 μg protein. Micro-dissected tissue was lysed in a buffer consisting of 80 µL 0.1 M NH 4 HCO 3 , pH 7.63 and 20% ACN at 95 °C in a heating block for 1 h followed by heating at 65 °C for 2 h with agitation (650 rpm). Porcine sequencing grade trypsin (Promega) was added to the samples at a 1:50 enzyme:protein ratio. Samples were incubated at 37 °C overnight and thereafter frozen at -80 °C and dried by vacuum centrifugation. Samples were stored at -80 °C until further processing.
Tandem Mass Tag (TMT) labeling of peptides and hydrophilic interaction liquid chromatography (HILIC) fractionation
Lyophilized peptide samples were resuspended in 30 µ L 100 mM TEAB (Sigma-Aldrich).
Five µL was consumed to assess protein concentration by BCA according to the manufacturer's protocol (Pierce™ BCA Protein Assay Kit, ThermoFisher Scientific, San Jose, CA). TMT labeling reagents (TMTsixplex™, ThermoFisher Scientific, San Jose, CA)
were equilibrated to room temperature and 41 µL anhydrous acetonitrile was added, followed by brief vortexing. Labeling reagent (8 µ L) was added to each of the peptide samples followed by incubation for 1 h at ambient temperature. An internal standard master reference mix was created by combining equal amounts of proteins from each patient sample in an independent microcentrifuge-tube. The internal standard reference mix was labeled with the TMT-126 reporter ion. Reactions were quenched by adding 2 µL of 5 % hydroxylamine and incubating at ambient temperature for 15 min. Samples and the internal reference standard were combined in a 1:1 ratio, frozen at -80 °C and vacuum dried. Samples were re-dissolved in 0.4 μL of 10% TFA, followed by addition of 3.6 μL of H 2 O and subsequently 36 μL of ACN (final volume of 40 μL peptides in 90% ACN, 0.1% TFA). The samples were injected onto an in-house-packed TSKgel Amide-80 HILIC 320 μm × 170 mm capillary HPLC column using an Agilent 1200 capillary HPLC system (Agilent Technologies, Santa Clara, USA). The peptides were resolved using a 54 min gradient from 90% ACN, 0.1% TFA to 60% ACN, 0.1% TFA at a flow rate of 6 μL/min. The fractions were automatically collected in a micro-well plate at 1 min intervals after UV detection at 210 nm, and the fractions were pooled according to UV detection to a total of 7 fractions, which were then dried by vacuum centrifugation. whereas methionine oxidation and deamidation were set as dynamic. Precursor mass tolerance was set to 8 ppm and fragment mass tolerance was set to 0.05 Da. Peptide data were extracted using Mascot significance threshold 0.05 and minimum peptide length 6. A minimum of 2 peptides were used for protein identification, and a minimum of 2 unique peptides were used for protein quantitation. False discovery rate (FDR) was calculated using a decoy database search and only high confidence peptide identifications (FDR < 1 %) were included. Protein expression data was log2 transformed and quantile normalized. Fold changes between recurrence and recurrence-free patients were determined by the ratio (x = recurrence/recurrence-free) raised to two to the power of x (2 x ).
Tandem mass spectrometry (LC-MS/MS) and quantitative protein expression analysis
Gene expression validation of CYPOR in online datasets
We used a previously established Kaplan-Meier plotter survival analysis platform to analyze the impact of CYPOR expression on survival in different breast cancer subtypes 30 
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CYPOR gene expression and the best performing threshold was used as cutoff in the Cox proportional hazard regression analysis 31 . KM plotter generated survival plots with hazard ratios, 95 % confidence intervals and log rank p-value for the selected gene probe (the best JetSet gene probe was selected). Accepted Article collaboration with a skilled pathologist. Blinded IHC scoring/assessment was performed by a trained pathologist. CYPOR low defines tumors with no expression to mild cytoplasmic staining, whereas CYPOR high describes tumors with complete and highly intense cytoplasmic staining ( Supplementary Fig 2) . ER and PR were classified as negative if <1% of tumor cells 
Patient tissue samples for immunohistochemistry
Statistical analysis
Kaplan-Meier survival analysis curves were generated for RFS and overall survival (OS) in This article is protected by copyright. All rights reserved.
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Results
High CYPOR expression is associated with shorter RFS in TNBC and lymph-node negative patients
Two patient cohorts were utilized in a hypothesis-generating LC-MS/MS proteomic study to identify proteins associated with outcome in TNBC. Cohort 1 consisted of 34 early-stage TNBC patients divided into two groups based on recurrence status within a 10-year follow-up period (with recurrence: n = 15, recurrence-free: n = 19) (Fig 1) . Cohort 2 consisted of 10 pairs of matched primary (Pri) and metastatic (Met) TNBC tumors (n = 20).
Clinicopathological characteristics of cohorts 1 and 2 are described in Supplementary Table   S1 . The global quantitative proteomics employing TMT-labeling and LC-MS/MS showed that CYPOR was significantly altered between the two groups in cohort 1 and demonstrated that high CYPOR expression was associated with poor prognosis of TNBC patients (p = 0.026, recurrence = 0.330, recurrence-free = -0.245, Log2 normalized relative expression, Fig   2A) . In cohort 2, CYPOR expression was high in both the primary tumors and the metastasis compared to the same internal standard as used in cohort 1 (Pri = 0.199, Met = 0.335, Log2 normalized relative expression, Fig 2B) .
To validate the findings from the MS analysis in a larger cohort of breast cancer patients, we investigated the prognostic value of CYPOR expression by Kaplan-Meier survival analysis in two different platforms: CYPOR gene expression of 249 primary TNBC tumors (cohort 3), 580 primary basal-like tumors (cohort 4) using KM-plotter 30 , and CYPOR protein expression of another cohort of 113 primary TNBC tumors (cohort 5) using IHC.
Kaplan-Meier survival analysis of CYPOR gene expression in cohorts 3 and 4 showed a significant correlation between high CYPOR expression and shorter RFS in TNBC and basallike patients and OS in basal-like patients, with insufficient patients to assess OS in TNBC
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Accepted Article patients (Figs 3 A and B , data not shown for OS for basal-like patients). Additionally, we examined the correlation between RFS of TNBC patients in cohort 3 and the expression of 12 P450 monooxygenases, which interact with CYPOR. Five of these (CYP2D6, p=0.039;
CYP1A2, p=0.031; CYP2A6, p=0.0057; CYP2E1, p=0.019; CYP26B1, p=0.047) showed significant correlation between high gene expression and shorter RFS in TNBC patients ( Supplementary Fig 1) . However, no noticeable difference in tissue expression or the type of substrates they metabolize was observed between these 5 P450 monooxygenases and the rest.
Next, we evaluated the data from IHC staining of tumors from cohort 5. In this analysis, CYPOR high corresponded to complete and intense cytoplasmic staining, while CYPOR low corresponded to absent to faint cytoplasmic staining ( Supplementary Fig 2) . Initially, we evaluated whether the IHC scores for the 34 samples used for the proteomic study correlated with the TMT-based expression values for CYPOR from that study, and a good correlation was indeed observed ( Supplementary Fig 3) . Kaplan-Meier survival analysis of cohort 5 revealed a significant correlation between high CYPOR protein expression and shorter RFS in TNBC patients (p = 0.017, HR = 2.73, 95% CI 1.20-6.19, median RFS: 59.4 vs 101 months for CYPOR high and CYPOR low , respectively) ( Fig 4A) , and no significant correlation between CYPOR expression and OS (p = 0.17, HR = 1.70, 95% CI 0.80-3.62, median OS:
106 vs 109 months for CYPOR high and CYPOR low , respectively) ( Fig 4B) . χ2 testing of the clinicopathological characteristics of patients at the time of surgery in the two groups revealed no significant differences relative to age, tumor size, tumor grade, nodal status, the expression of the proliferation marker Ki-67, adjuvant treatment or type of surgery (Table 1) .
Subsequently, we subdivided the TNBC patients into basal-like (EGFR+ or CK14+ TNBC)
and non-basal-like (EGFR-/CK14-TNBC) breast cancer tumors. High CYPOR protein expression in basal-like breast cancer patients correlated with a significantly shorter RFS, but not OS (RFS: p = 0.025, HR = 3.47, 95% CI = 1.17-10.27) ( Figs 4C and D) . No significant correlation was found between CYPOR protein expression and RFS or OS in non-basal-like breast cancer patients ( Figs 4E and F) . We also subdivided the tumors of this cohort based only on EGFR expression into EGFR+ and EGFR-subgroups. Correlation between CYPOR expression and RFS in the two subgroups showed that in the EGFR-group, CYPOR high expression significantly correlated with shorter RFS (p = 0.044, HR = 2.15, 95% CI = 1.02-4.53), while a similar trend in the EGFR+ group did not reach significance (p = 0.077, HR = 2.92, 95% CI = 0.89-9.62). (Supplementary fig. S4A and B) . However, as the number of patients in the latter group was small (CYPOR high n=22 and versus CYPOR low n = 8), firm conclusions cannot be made.
Nodal status is one of the strongest prognostic factors in breast cancer, and a highly significant correlation between tumor-positive lymph node status (N+) and shorter RFS and OS in cohort 5 was observed (RFS: p < 0.0001, HR = 3.24, 95% CI = 1.80-5.85, median RFS: 115 vs 56 months for N-and N+, respectively; OS: p < 0.0001, HR = 4.41, 95% CI = 2.29-8.51, median OS: 120 vs 80 months for N-and N+, respectively) ( Supplementary Fig   5A and B) . Cohort 5 was therefore subdivided according to tumor nodal status (N+ vs N-) and the survival outcome analyzed in correlation to CYPOR protein expression. High CYPOR expression correlated significantly with a shorter RFS, but not OS, in TNBC/Npatients (median RFS: 106 vs 116 months for CYPOR high and CYPOR low, respectively; median OS: 116 vs 118 months for CYPOR high and CYPOR low, respectively) ( Fig 4G and H) , while no correlation between CYPOR expression and patient outcome was observed in the TNBC/N+ subgroup (p = 0.69, data not shown). No significant correlation between CYPOR expression and RFS or OS was observed in N-non-basal-like breast cancer patients ( Supplementary Figs 6A and B ).
Univariate and multivariate Cox proportional hazard regression analysis were performed to ascertain the prognostic impact of the different variables of cohort 5, including age, menopausal state, tumor size, nodal status and CYPOR expression on RFS. Univariate analysis revealed a significant association between nodal status and CYPOR protein expression on RFS in TNBC patients, and these significant variables were subsequently used in the multivariate analysis ( Table 2 ). As expected, nodal status at diagnosis correlated significantly with RFS for the TNBC patient group in the multivariate analysis. Interestingly, multivariate analysis revealed that CYPOR expression was an independent prognostic factor of RFS, but not for other endpoint variables in TNBC patients ( Table 2) . No correlation between CYPOR expression and endpoints in multivariate analysis of the basal-like and nonbasal-like breast cancer subgroups were found, however, basal-like breast cancer patients showed significance in a univariate analysis ( Supplementary Tables S3 and S4 ). This data establishes high CYPOR expression as an independent biomarker of shorter RFS in TNBC with an associated average two-fold higher risk of recurrence for patients with high vs low CYPOR-expressing primary tumors.
Discussion
In this study, we show that high cytoplasmic expression of Cytochrome P450 reductase (CYPOR) is an independent prognostic biomarker of short RFS of TNBC patients. CYPOR was initially found to be associated with TNBC patient outcome in two independent mass spectrometric datasets of TNBC patient tumors, and the correlation between expression levels and RFS was subsequently confirmed by an independent IHC-based analysis of a Danish TNBC cohort of 113 patients and with publicly available gene expression data sets from 249 TNBC and 580 basal-like breast cancer patients.
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CYPOR has been shown to modulate the induction of erythropoietin under hypoxia, possibly through enhanced DNA-binding of hypoxia inducible factor-1 (HIF-1) and a correlation between CYPOR and VEGF mRNA levels has also been observed 32 . Hypoxic conditions are a common phenomenon in solid tumors, particularly aggressive tumors, and HIF-1 stabilization with concomitant activation of vascular endothelial growth factor results in angiogenesis, a hallmark of cancer 33 . Taken together, these data may suggest a possible connection between angiogenesis and elevated CYPOR expression, potentially explaining the observed shorter RFS in CYPOR high patients.
In vitro studies have demonstrated the ability of CYPOR to reduce pro-drug variants to their active form. In MCF-7 cell lines, the exogenous addition of CYPOR together with mitomycin C (MMC) potentiated toxicity with an approximately 6-fold reduction in IC50 from 0.12 to 0.02 µg/ml 27 Our study is the first to demonstrate a correlation between high CYPOR expression and shorter RFS in TNBC and basal-like patients, while correlation with CYPOR expression and OS was only observed at the gene expression level for basal-like patients. Our study shows that CYPOR is an independent prognostic biomarker of shorter RFS with a two-fold higher risk of recurrence in TNBC patients with high CYPOR expression in primary tumors.
Patients with low CYPOR expression in primary tumors remained recurrence-free for at least 10 years. Thus, we hypothesize that high CYPOR expression (determined at either the gene or protein level) is an independent prognostic biomarker useful for stratifying TNBC and basal-like breast cancer patients to alternative adjuvant treatment and/or more aggressive surveillance.
We consider these findings important for further analysis into the molecular mechanisms underlying the effect of CYPOR expression on recurrence. Although there were no significant differences in the type of adjuvant treatment the patients with CYPOR high and CYPOR low tumors received, CYPOR and P450 monooxygenases are involved in metabolism of several drugs, which should be taken into consideration before future clinical trials by testing CYPOR-interacting drugs in an adjuvant setting in patients with high CYPOR TNBC.
To determine whether CYPOR provides additional clinically-useful prognostic information for TNBC patients, these retrospective findings should be followed by a suitably powered, prospective observational study. However, reliable survival data requires a long follow-up time. Mast. and lump.
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Triple negative breast cancer is highly heterogeneous and frequently aggressive, and finding molecular markers that correlate with outcomes can help refine treatment strategies. Previous work has pointed to cytochrome P450 reductase (CYPOR) as a marker associated with patient outcomes for triple negative breast cancer. These authors looked at the correlation between CYPOR expression and time to cancer recurrence. Patients with high levels of cytochrome P450 reductase saw their cancers return faster. CYPOR, then, may help identify patients that could benefit from more aggressive treatment and careful monitoring.
